Association of significant elevation of serum osteopontin (OPN) with aggressive and hypoxic glioblastoma subgroup supports the function of OPN in cancer aggressiveness and high serum OPN levels may be a marker of hypoxia. This evidence concerns the gene SPP1 and glioblastoma.